Rehmann Capital Advisory Group Lowers Stock Holdings in Haleon plc (NYSE:HLN)

Rehmann Capital Advisory Group lowered its position in shares of Haleon plc (NYSE:HLN) by 9.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 13,675 shares of the company’s stock after selling 1,364 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Haleon were worth $147,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. AE Wealth Management LLC raised its holdings in shares of Haleon by 6.1% during the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock valued at $159,000 after buying an additional 1,098 shares in the last quarter. Lake Street Advisors Group LLC raised its stake in shares of Haleon by 5.4% during the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock worth $237,000 after acquiring an additional 1,143 shares in the last quarter. Endowment Wealth Management Inc. raised its stake in shares of Haleon by 9.9% during the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock worth $106,000 after acquiring an additional 1,161 shares in the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Haleon by 18.5% in the 3rd quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company’s stock worth $84,000 after acquiring an additional 1,238 shares during the last quarter. Finally, Lester Murray Antman dba SimplyRich boosted its stake in shares of Haleon by 2.9% in the 2nd quarter. Lester Murray Antman dba SimplyRich now owns 45,519 shares of the company’s stock valued at $375,000 after purchasing an additional 1,301 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HLN has been the topic of a number of analyst reports. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley lifted their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $10.95.

Haleon Stock Up 0.3 %

Shares of Haleon stock opened at $9.76 on Friday. The company’s 50 day moving average price is $9.75 and its 200-day moving average price is $9.51. Haleon plc has a 52-week low of $7.89 and a 52-week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $44.18 billion, a price-to-earnings ratio of 28.71, a P/E/G ratio of 2.95 and a beta of 0.28.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.